The firm has developed a new classifier for bladder cancer and continues to work with pharma companies in the lung cancer space.
CFDRC obtained iXG's high-throughput antimicrobial discovery platform, EMAD (extremophilic microbiome antimicrobial discovery).
Microbiotica will use its metagenomics microbiome platform to help Genentech develop biomarkers, targets, and medicines for inflammatory bowel disease.
Centogene will help Aldeyra identify patients with Sjögren-Larsson Syndrome, a rare genetic disease for which Aldeyra is developing a treatment.
The company will use the funds to further develop its cloud-based alternative splicing analysis platform for drug discovery.
OncoDNA will provide patient-enrollment services for an ongoing clinical study of Kura's head and neck squamous cell carcinoma drug tipifarnib.
The group will combine VIB's sequencing technology with Verge's machine learning platform to study banked tissue samples at UCSD in a drug discovery effort.
BioClin is developing a monoclonal antibody-based treatment for relapsed/refractory metastatic urothelial carcinoma with FGFR3 molecular alterations.
Genome-wide association study hits can uncover potential therapies for conditions like inflammatory bowel disease, a Biology of Genomes speaker said.
The five CROs will be able to offer DSP analyses to their customers through a technology access program ahead of NanoString's planned platform launch in 2019.
ReviveMed's technology uses artificial intelligence-based analysis of metabolomics data for drug discovery and development.
Veracyte will use its Afirma assay to analyze thyroid cancers and inform Loxo's drug development pipeline for targeted therapies.
Element Genomics' technology will increase UCB's pipeline, focusing on target discovery and interpretation in disease relevant systems.
The company will design and validate a test using its Exolution isolation kit, which can stratify and monitor patients in Intezyne's clinical trials of IT-139.
Nohla will use Karius' NGS plasma test for pathogen detection in a randomized trial evaluating Nohla's lead product, a cellular therapy called NLA101.
Researchers from Rockefeller University sifted through soil microbiomes for genes linked to the function of calcium-dependent antibiotics.
Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
The partnership will integrate Ambry Genetics' and Invicro's technologies to expedite new drug discovery and development.
The financing will be used to advance the firm's drug discovery platform, which combines high-throughput wet lab experimentation with artificial intelligence.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.